Skip to main content
Publish date:

Monday's Health Winners & Losers

Shire and New River are higher.
Author:

Acorda Therapeutics

(ACOR) - Get Acorda Therapeutics, Inc. Report

shares jumped 11.3% to $16.58 despite a downgrade by analysts at Rodman & Renshaw.

The firm lowered its rating on Acorda shares from market-outperform to market-perform without a target price. The previous price target was $14.

Shire

(SHPGY)

and

New River Pharmaceuticals

(NRPH)

saw their shares jump Monday after regulators said their attention-deficit hyperactivity disorder drug was approvable.

Shares of Shire were up 8.7% to $53.70, while New River's shares soared to $38.53, up 47%. The Food and Drug Administration says the drug is approvable but is contingent on a schedule determination by the U.S. Drug Enforcement Administration, Shire said in a press release late Friday. No additional trials need to be conducted for the drug to be cleared.

Regulators have given their blessing to Brovana, a drug from

Sepracor

(SEPR)

that treats airways that have been constricted because of chronic obstructive pulmonary disease.

The drug is a long-acting solution meant to be used with a nebulizer, a device that converts liquid into a fine mist. The Food and Drug Administration approval was announced late Friday. Following the regulatory clearance, shares of Sepracor were up 97 cents, or 2%, to $51.17.

TheStreet Recommends

Vaccine developer

Crucell

(CRXL)

received a $16.2 million contract from the National Institutes of Health's allergy and infectious disease group to develop an HIV vaccine.

Through the contract, Crucell will be collaborating with

Charles River Laboratories

(CRL) - Get Charles River Laboratories International, Inc. Report

and the Beth Israel Deaconess Medical Center at Harvard Medical School. The program will also be supported by the National Institute of Allergy and Infectious Diseases Vaccine Research Center. Shares of Crucell were up 2.3% to $23.70.

Bristol-Myers Squibb

(BMY) - Get Bristol-Myers Squibb Company Report

,

Merck

(MRK) - Get Merck & Co., Inc. (MRK) Report

and

Gilead

(GILD) - Get Gilead Sciences, Inc. (GILD) Report

have submitted an application to European regulators in an effort to gain approval for the HIV drug Atripla.

Bristol's shares fell 1% to $24.18, Merck's stock was 0.5% lower to $41.66, and Gilead dipped 0.8% to $64.82.